ClinicalTrials.gg
RecruitingNCT04126018Updated Jan 13, 2026

Comparative Imaging Assessment of Valvular Heart Disease

An observational study in Valve Heart Disease, Aortic Stenosis and Aortic Regurgitation, sponsored by The Cleveland Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by The Cleveland Clinic · Observational

How we know

From the registry’s dates

  • Started Aug 2019; still recruiting 7 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 111 studies in Heart Valve Diseases with a site in United States — 39 open to participants now, 50 under way, none of them phase 3. Heart Valve Diseases · United States.

Planned enrollment
25th of 45
200 · median 353
Started
2019
with 8 others
Observational
45 of 111
24 open now
Primary completion
2027-12
later than 26 of 49 live
Registered
60th of 111
by date
Lead sponsor
4 of 111
The Cleveland Clinic

Among the 111 studies in Heart Valve Diseases with a site in United States, this one is the 25th largest by planned enrollment of the 45 observational ones that give a count, is one of 9 that started in 2019, is one of 45 observational ones, reaches primary completion later than 26 of the 49 other live ones, and was the 60th registered.

Heart Valve Diseases

557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.

Browse Heart Valve Diseases studies →

Open to participants now

39 of the 111 studies in Heart Valve Diseases with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Heart Valve Diseases with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to compare the various 2D and 3D methods of valvular heart disease quantification (Doppler, PISA, VCA, volumetric method) and strain with cardiac magnetic resonance (CMR) measurements of left and right ventricular systolic function strain and myocardial fibrosis assessment.

Read the detailed description

The objective of this study is to compare the accuracy of 3D TTE to 2D TTE in assessing the severity of valvular heart disease in patients with aortic stenosis, aortic regurgitation, and mitral valve regurgitation by comparing this to the reference standard of cardiac magnetic resonance (CMR) in subjects with different etiologies and mechanisms of valvular lesions and to the integrative method of valvular lesion grading as recommended by inter-societal guidelines. Another objective is to assess prevalence of focal and diffuse myocardial fibrosis as assessed by CMR in patients with aortic stenosis, aortic regurgitation and mitral regurgitation. In addition, the investigators aim to determine whether severity of myocardial fibrosis predicts onset of symptoms, referral for valve surgery and adverse ventricular remodeling. The investigators also aim to look at patients who will be undergoing CRT implant to predict their response to therapy.

At baseline, the Rapid Assessment of Physical Activity questionnaire and the Kansas City Cardiomyopathy Questionnaire will be completed. A 6-12 month follow-up is required and will include an abbreviated non-contrast research cardiac MRI and subject questionnaires.

Other follow-up will include using electronic medical records and the Social Security Death Index database for outcomes such as death, hospitalization for heart failure, mitral or aortic valve interventions and cardiovascular death.

Select patients will be asked to undergo a supine bicycle exercise stress MRI at enrollment. Approximately 40 subjects will be included in this substudy.

Additional exclusion criteria for this substudy:

  • Unable to pedal a supine bicycle
  • Require supplemental oxygen

During the exercise stress MRI, patients will be asked to cycle on a supine bike that will be mounted on the MRI platform. During this test, a caregiver will be present. An electrocardiogram (ECG) will be used to obtain tracings of cardiac activity. Respirations, blood pressure, and heart rate are also monitored during exercise. The test is continued until peak exercise level or target heart rate is achieved. As soon as the exercise portion is complete, MRI images will be acquired. When the test is complete, patients will be monitored until ECG, heart rate, and breathing have returned to baseline. Patients will be assessed for symptoms such as chest pain, dyspnea, leg pain, dizziness, or fatigue and may be given medications or instructed to stop the test early as necessary.

03

Conditions studied

  • Valve Heart Disease
  • Aortic Stenosis
  • Aortic Regurgitation
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with suspected chronic AS, AR, MR or heart failure with reduced ejection fraction being evaluated for CRT implantation referred for clinically indicated CMR and echocardiography by their cardiologists.. CMR and echocardiography will be clinically indicated in this study group.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-90 years of age
  • Suspected moderate or severe MR,AR or AS on the basis of prior known clinical history or clinical exam.
  • Suspected CRT "non-responder" with an implanted MRI compatible CRT device and reduced

Exclusion criteria

Exclusion Criteria:

  • Acute traumatic cardiac injury
  • Aortic dissection or aortic root rupture
  • Congenital heart diseases such as patent ductus arteriosus, coarctation of aorta, ASD and VSD
  • Presence of A-V fistula or intracardiac shunts
  • Any to CMR
  • Moderate or severe dysfunction in multiple valves
  • Patients with significant claustrophobia
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Mitral Valve Regurgitation

    Patients with moderate or severe (3+ or 4+) mitral valve regurgitation on the basis of prior known clinical history or clinical exam.

    Diagnostic Test: MRI with strain measurement · Diagnostic Test: Echocardiography

  • Aortic Valve Regurgitation

    Patients with moderate or severe (3+ or 4+) aortic valve regurgitation on the basis of prior known clinical history or clinical exam.

    Diagnostic Test: MRI with strain measurement · Diagnostic Test: Echocardiography

  • Aortic Stenosis

    Patients with moderate or severe (3+ or 4+) aortic stenosis on the basis of prior known clinical history or clinical exam.

    Diagnostic Test: MRI with strain measurement · Diagnostic Test: Echocardiography

  • Patients referred for CRT Implantation

    Patients who meet clinical guideline criteria for CRT implantation with EF \< 40%

    Diagnostic Test: MRI with strain measurement · Diagnostic Test: Echocardiography

Interventions

  • Diagnostic testMRI with strain measurement

    CMR measurements of left and right ventricular systolic function strain and myocardial fibrosis

  • Diagnostic testEchocardiography

    Doppler, PISA, VCA, volumetric method as performed during echocardiography

06

What researchers measure

Primary outcomes

  1. Change in MRI Quantified LVEDVi

    10% Change from Baseline - units of measure cc/m2

    Time frame: 6 months

  2. Change in MRI Quantified LVESVi

    15% Change from Baseline - units of measure cc/m2

    Time frame: 6 months

  3. Change in MRI Quantified LV Strain

    5% Change from Baseline

    Time frame: 6 months

  4. Change in MRI LVEF

    5% Change from Baseline

    Time frame: 6 Months

  5. Change in Kansas City Cardiomyopathy Questionnaire Answers

    Change in quality of life related to heart failure symptoms.

    Time frame: 6 Months

  6. Change in Physical Activity Questionnaire Answers

    Change in physical activity level due to heart failure symptoms.

    Time frame: 6 Months

  7. All-cause mortality

    number of patients expired

    Time frame: 6 Months

  8. Development of class I or IIa indication for valve surgery

    The recommended indications for surgery include: development of symptoms, LV dysfunction (LV end-systolic diameter ≥45 mm or LV ejection fraction ≤60%), and new onset of atrial fibrillation or pulmonary hypertension (systolic pulmonary artery pressure \>50 mm Hg at rest).

    Time frame: 6 Months

Secondary outcomes

  1. Accuracy of echocardiography as compared with MRI

    Comparison of MRI measurements based on standard of care echocardiography.

    Time frame: 6 Months

07

Study locations

1 of 1 sites recruiting
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Recruiting
    • Deborah Kwon, M. D. · Contactkwond@ccf.org · 216-444-8526
    • Richard Grimm, MD · Sub investigator
    • Mina Chung, MD · Sub investigator
    • Wlson Tang, MD · Sub investigator
    • Tom Wang, MD · Sub investigator
    • Christopher Nguyen, Ph.D · Sub investigator
    • Tiffany Dong, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2019 (actual). Primary completion is estimated for Dec 2027, 100 months after the start.

Of 96 non-industry observational studies under Heart Valve Diseases, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 212. This study's planned 100 months is above that.

Counting every sponsor, half of 116 studies reached it within 67 months; a quarter within 29 and three quarters within 212.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2019
First posted
Oct 14, 2019
StartActual
Aug 23, 2019
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04126018
Responsible party
Deborah Kwon, MD (Principal Investigator, The Cleveland Clinic) — Principal investigator
First posted
Oct 14, 2019
Start date
Aug 23, 2019
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 13, 2026

Study contacts

Deborah Kwon, M. D.
Contact
kwond@ccf.org
216-444-8526
Deborah Kwon, M. D.
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion